Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
PLRZRaanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products.
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
PLRZRa’anana, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announces that it has successfully completed a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding its PL-14 Allergy Blocker product, a novel nasal spray designed to provide protective intranasal barrier functionality.
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
PLRZRa’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to respiratory defense. Polyrizon Ltd. (Nasdaq: PLRZ), a development-stage biotechnology company, aims to transform a bold lab-born vision into a scalable reality. With the recent announcement of a pivotal manufacturing milestone, Polyrizon is no longer just a promising startup—it is advancing its efforts to develop non-pharmacological solutions that could shield global populations from seasonal woes and beyond.
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
PLRZRa’anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced the successful completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform. This achievement marks a critical step toward supporting upcoming clinical and regulatory activities, as well as potential commercial readiness in the future.
Polyrizon Regains Compliance with Nasdaq Listing Requirements
PLRZRa’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor (the “Hearings Advisor”) of the Office of the General Counsel of the Nasdaq Hearings Panel (the “Nasdaq Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with all applicable listing requirements.
Polyrizon Announces Preclinical Results From Study Evaluating Its Trap & Target Platform Showing Formulation Achieved Targeted Deposition In Upper Regions Of Nasal Cavity
PLRZTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
PLRZPolyrizon Receives Nasdaq Delisting Notice
PLRZPolyrizon Announces Results From Recent Ex Vivo Studies Demonstrating Mucoadhesive Strength And Extensive Nasal Surface Coverage Of Its Proprietary Formulation Platform
PLRZPolyrizon Launches Preclinical Studies For Intranasal Benzodiazepines Targeting $3.15B Acute Seizure Market
PLRZPolyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On?
PLRZShares of Polyrizon surged 243% Friday afternoon. The stock is higher following a reversal in corporate plans from Thursday.
Reported May 1, 2025: Polyrizon Announced The Planned Reverse Share Split Of The Company's Ordinary Shares At The Ratio Of 1-For-10 That Was Previously Announced On May 1, 2025, Will Not Be Effectuated
PLRZPolyrizon Announced Preliminary Safety Study For A Formulation Of Its PL-14 Allergy Blocker, Conducted On Fully Differentiated Human Nasal Tissue Using The Mucilair Model, The Study Demonstrated Strong Local Tolerability
PLRZPolyrizon Receives Nasdaq Minimum Bid Price Notification
PLRZPolyrizon Announces $17M Private Placement At $0.48/Unit
PLRZPolyrizon Structures Clinical Strategy For PL-14 Ahead Of FDA Pre-Submission Meeting
PLRZPolyrizon Announces The Initiation Of Preclinical Studies For Intranasal Benzodiazepines, A Treatment For Acute Repetitive Seizures And Status Epilepticus, Using Its Proprietary Drug Delivery Platform
PLRZPolyrizon Signs Non– Binding LOI With A Biotech Company Focused On Psychedelic-derived Therapeutics, To Develop A Novel Intranasal Formulation For Psychedelic-Based Treatment Applications
PLRZPolyrizon Launches Preclinical Studies For Intranasal Naloxone To Combat Opioid Overdose
PLRZPolyrizon Reports Initiation Of Preclinical Studies For Intranasal Naloxone For Opioid Overdose Treatment
PLRZPolyrizon Shares Halted On Circuit Breaker
PLRZ